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Abstract 0 The pharmacokinetics and pharmacodynamics of pirmenol
enantiomers were investigated in coronary artery ligated mongrel dogs.
Reduction in frequency of premature ventricular complexes (PVCs) was
determined following intravenous administration of 5-mg/kg doses of
racemic pirmenol (n ) 5), (+)-pirmenol (n ) 4), and (−)-pirmenol (n )
4), each given as a 5-min infusion. Electrocardiographic signals and
blood samples were obtained serially over a 4-h period. Pirmenol
enantiomer concentrations in plasma were determined by a stereospecific
assay. Following the racemate dose, (−)-pirmenol had 47% lower
clearance and 33% lower steady-state distribution volume than (+)-
pirmenol. These differences could be mostly explained by stereoselective
plasma protein binding, reflected in a 58% higher unbound fraction for
(+)-pirmenol compared with (−)-pirmenol following racemate administration.
Unbound pirmenol distribution volumes were nearly identical for both
enantiomers, and unbound clearance was only 16% lower for (−)-pirmenol
than (+)-pirmenol following administration of the racemate. Similar trends
were observed for pirmenol enantiomers administered individually. Both
pirmenol enantiomers were equally effective in arrhythmia suppression.
The antiarrhythmic response of coronary artery ligated dogs to pirmenol
was described by a sigmoid Emax model, and no statistically significant
differences were observed in the pharmacodynamic parameters [i.e., EC50
(plasma concentration at 50% of maximum drug effect), S (constant that
reflects the sigmoidal shape of the effect−concentration curve), and EC90
(plasma concentration at 90% of maximum drug effect)] for (+)-pirmenol,
(−)-pirmenol, or pirmenol racemate.
Introduction
Stereoisomerism is an important consideration in drug
development because the enantiomers of an optically active
compound may differ in their interaction with other chiral
molecules. Many biological molecules are chiral in nature,
so the potential exists for selective interactions between these
molecules and opposing enantiomers of chiral drugs. Enan-
tiomers of a drug may show substantial differences in their
pharmacological activity, and when this occurs, enantiomer
differences in pharmacokinetics can become important deter-
minants of drug response.
Pirmenol is a chiral compound, and the racemic mixture is
being investigated as an antiarrhythmic agent. Pirmenol is
considered as a Class I antiarrhythmic because its primary
effect is blocking sodium channels in the cardiac cell mem-
brane. Many other drugs in the same class are chiral,
including disopyramide, cibenzoline, tocainide, mexiletine,
flecainide, encainide, and propafenone, and are administered
as racemic mixtures.
Pirmenol racemate was shown to be effective in suppression
of premature ventricular contractions (PVCs) following coro-
nary artery ligation in dogs.1-3 However, antiarrhythmic
effects may not be produced equally by both enantiomers. In
dog models of ventricular arrhythmia, enantiomers of tocain-
ide,4 flecainide,5 propranolol,6 and sotalol7 showed equivalent
antiarrhythmic effects, but mexiletine demonstrated a ste-
reoselective difference where R-(-)-mexiletine was more
potent in prevention of ventricular tachycardia than S-(+)-
mexiletine in dogs.8 Furthermore, both disopyramide and
propranolol showed stereoselective pharmacokinetic prop-
erties.9-13 Clearance of S-(+)-disopyramide in dogs was nearly
50% higher than that of R-(-)-disopyramide, with no enan-
tiomer difference in distribution volume.9,14 Cook et al.10 also
observed stereoselective clearance of disopyramide in dogs,
demonstrating a 40% higher renal clearance and greater first-
pass metabolism for S-(+)-disopyramide, withN-dealkylation
being a stereoselective metabolic pathway. In addition,
several investigators have reported stereoselective hepatic
metabolism of S-(-)-propranolol in dogs.11-13,15
In this study, possible differences in pharmacokinetics and
pharmacodynamics of pirmenol enantiomers were investigated
to provide information regarding any potential benefit in the
use of either pirmenol enantiomer rather than the racemate.
To determine the relative contribution of pirmenol enanti-
omers to the overall antiarrhythmic effect, (+)-pirmenol, (-)-
pirmenol, and pirmenol racemate were each tested in the
model of induced ventricular arrhythmia in dogs, which was
initially used in the study of pirmenol racemate. Pharmaco-
kinetics of pirmenol enantiomers were also studied in these
animals.
Experimental Section
Study DesignsReduction in frequency of PVCs following intra-
venous (iv) administration of 5-mg/kg doses of pirmenol racemate (n
) 5), (+)-pirmenol (n ) 4), and (-)-pirmenol (n ) 4) was determined
in coronary artery ligated mongrel dogs of either gender weighing
8.1 to 13.0 kg (mean 10.4 kg). Dogs were anesthetized with pento-
barbital sodium (35 mg/kg, iv), and the left anterior descending
coronary artery was ligated by a two-stage procedure as described
by Harris.16 A lead II electrocardiogram (ECG) was monitored on
the first day after surgery with a Gould 220 polygraph. Analysis of
the ECG record was performed by the method of Moran et al.17 in
which ventricular beats of apparent sinus origin were considered
normal and all other ventricular beats were classified as ectopic. Dogs
were excluded from testing if >50% normal sinus beats were observed
or if total ventricular rate exceeded 200 beats/min. The dogs were
studied in the conscious state (1 day post-infarction) while resting
comfortably suspended in slings.
Predose baseline arrhythmia was determined as the average
number of PVCs/min during the final 20 min before dosing. The ECG
readings (20 s each) were obtained every minute during the infusion
and for the first 5 min after the infusion, every 5 min for the first
hour post-infusion, and every 15 min from 1 to 4 h following the end
of the infusion. Additional ECG readings were obtained 1 min before
and 1 min after each blood sampling time, and the three ECG values
(PVCs/min) were averaged. Pirmenol doses were dissolved in 10 mL
of 0.9% saline and administered as a 5-min infusion via the femoral
artery. Blood samples (1.5 mL) were obtained before dosing (blank),
at the end of the 5-min infusion, and at 5, 10, 20, 30, 45, 60, 90, 120,X Abstract published in Advance ACS Abstracts, February 1, 1997.
© 1997, American Chemical Society and S0022-3549(96)00369-3 CCC: $14.00 Journal of Pharmaceutical Sciences / 443
American Pharmaceutical Association Vol. 86, No. 4, April 1997
180, and 240 min post-infusion. Plasma was separated and assayed
the same day or stored frozen at -20 °C until analysis.
Quantitation of Pirmenol EnantiomerssPlasma pirmenol
enantiomer concentrations were determined by a stereospecific liquid
chromatographic assay,18 except that a 0.25-mL sample (diluted with
0.25 mL of blank dog plasma) was used. Briefly, racemic pirmenol
and internal standard [(+)-propranolol] were isolated from dog plasma
by a three-step extraction procedure using toluene, 0.1 N HCl, and
hexane, respectively. A cellulose-bonded chiral analytical column
(Chiralcel OJ) was used, with a mobile phase consisting of hexane:
isopropanol:diethylamine (98.9:1.0:0.1) and with detection by ultra-
violet (UV) absorbance at 262 nm. Linear calibration curves were
obtained in the concentration range of 0.0200 to 5.00 µg/mL for each
enantiomer. The precision of the method was e7.1% for both
enantiomers, and bias was (2.2% for (+)-pirmenol and (1.5% for (-)-
pirmenol. Neither enantiomer was observed in chromatograms
following administration of the opposite enantiomer to coronary artery
ligated dogs. Therefore, pirmenol enantiomer conversion did not occur
in vivo nor did it occur during sample analysis.
Unbound concentrations were determined in each study sample
by equilibrium dialysis. Plasma containing pirmenol (0.75 mL) was
dialyzed against an equal volume of isotonic pH 7.4 phosphate buffer
in a 37 °C shaking water bath for 4 h (equilibrium was reached, as
indicated by preliminary experiments). Plasma and buffer samples
were assayed for pirmenol enantiomer concentrations by a liquid
chromatographic method.18
Pharmacokinetic Data AnalysissPostinfusion plasma pirmenol
concentration (Cp)-time (t) data were fitted to the following polyex-
ponential equation:
in which parameter estimates (Yi, λi) were obtained by nonlinear least-
squares regression (RSTRIP, Version 4, MicroMath Scientific Soft-
ware, Salt Lake City, UT). The number of exponents used in the
equation and weighting factor (1, 1/concentration, or 1/concentration2)
were selected based on coefficient of determination (r2), standard
deviation of the parameter estimates, and visual inspection of the
residuals. Coefficients were corrected for infusion time (T) with the
following equation:
Pharmacokinetic parameters were then calculated with standard
equations.19,20 The pharmacokinetics of unbound pirmenol were
determined by the same methods.
Linear or nonlinear binding was assessed from a plot of Cb′′ as a
function of Cf′. For linear binding, fraction unbound in plasma (fu)
was calculated with eq 321:
in which Cf′ is the unbound concentration of pirmenol in buffer after
dialysis, and Cb′′ is the volume-corrected bound concentration of
pirmenol in plasma after dialysis.
For nonlinear binding, Cb′′ versus Cf′ data were best fit to a single
Langmuir equation:
where P(1) and P(2) are capacity and dissociation constants, respec-
tively. Nonlinear regression was performed with the programMINSQ
II (Version 1.02, MicroMath Scientific Software, Salt Lake City, UT),
with a weighting factor of unity. Goodness of fit criteria included
coefficient of determination (r2), standard deviation of parameter
estimates, and visual inspection of residuals. Since total concentra-
tion (Cp) is the sum of bound (Cb) and unbound (Cf) concentrations
in plasma, total concentration can be expressed as follows:
Equation 5 can be rearranged to a quadratic equation (eq 6) that was
solved for unbound concentration (Cf) using the total concentration
in the original plasma sample (Cp) and estimates of P(1) and P(2):
The time-averaged fraction unbound in plasma (fu) was then esti-
mated as follows:
Pharmacodynamic Data AnalysissThe pharmacologic effect of
pirmenol was measured as the percent reduction in PVCs/min from
the pre-study baseline value. At each blood sampling time, PVCs
were averaged for ECG readings obtained 1 min before, during, and
1 min after the sampling time. Effect measurements obtained
postinfusion without simultaneous blood sample collection were paired
with plasma drug concentrations that were calculated with parameter
estimates obtained from pharmacokinetic data analysis. Effect-
concentration profiles were fitted to a sigmoidEmax equation, as shown
in eq 8:
where E is the percent reduction in PVCs from baseline; Emax is the
maximum drug effect; C is the plasma pirmenol concentration (µg/
mL); EC50 is the plasma concentration at 50% of Emax (µg/mL); and S
is a constant that reflects the sigmoid shape of the effect-concentra-
tion curve. The Emax value was held constant at 100% because
complete abolition of PVCs was evident with pirmenol. The EC50 and
S values were estimated by nonlinear least squares regression with
the programMINSQ II and a weighting factor of unity. Because effect
is defined as percent reduction in PVCs, the maximum possible effect
that can be achieved is 100%. The effective therapeutic concentration
was determined as the plasma drug concentration at 90% PVC
reduction (EC90, µg/mL). The EC90 values were calculated with the
parameter estimates and a rearrangement of eq 8, such that EC90 )
EC50/(0.111)1/S.
Statistical AnalysissEnantiomer differences in mean pharma-
cokinetic parameters were evaluated by a paired t test following
administration of pirmenol racemate and an unpaired t test following
administration of the individual enantiomers. Mean pharmacokinetic
parameters following the racemate dose were compared with param-
eters obtained following the enantiomer dose by unpaired t tests.
Mean pharmacodynamic parameters were compared by analysis of
variance. A p value of e0.05 was considered significant in all
statistical tests.
Results and Discussion
Pharmacokinetics of Pirmenol EnantiomerssPir-
menol plasma concentration-time data were fitted to eq 1
with either 1, 2, or 3 exponents. In each case, a weighting
factor of 1/concentration2 was used. Coefficients of determi-
nation ranged from 0.968 to 0.998 for those analyses using
total pirmenol, and from 0.893 to 0.999 for those analyses
using unbound pirmenol. Pharmacokinetic parameters for
total and unbound pirmenol enantiomers following the race-
mic dose and following individual enantiomer administration
are given in Table 1. Plasma total (-)-pirmenol concentra-
tions exceeded total (+)-pirmenol concentrations following
administration of the racemate as well as following separate
administration of each enantiomer at equal doses (Figure 1).
The AUC(0-∞) values were approximately twofold greater for
total (-)-pirmenol than for total (+)-pirmenol following pir-
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cant (S). The difference between AUC(0-∞) values following
individual enantiomer administration was not statistically
significant (NS) even though total (-)-pirmenol AUC(0-∞) was
44% greater than for total (+)-pirmenol. Clearance of total
drug was 47% lower (S) for (-)-pirmenol than for (+)-pirmenol
following the racemate dose and 32% lower (NS) for (-)-
pirmenol following individual enantiomer doses. Similar to
the significantly higher plasma clearance for (+)-pirmenol
than for (-)-pirmenol, stereoselective clearance was also
observed for disopyramide and propranolol in dogs, where
clearance of S-(+)-disopyramide and S-(-)-propranolol ex-
ceeded their R-enantiomers by 40 to 50% and by two- to
threefold, respectively.9-12,14 Volume of distribution param-
eters (V1, Vss, Varea) were ∼50% larger for total (+)-pirmenol
than for total (-)-pirmenol (S) following the racemate, and
10-49% larger for (+)-pirmenol than for (-)-pirmenol (NS)
following individual enantiomer administration. There were
no significant differences between enantiomers in elimination
half-life and mean residence time whether pirmenol was given
as the racemate or the individual enantiomers.
Although the trends in pharmacokinetic differences were
similar following both individual pirmenol enantiomer and
racemate administration, none of these enantiomer differences
were statistically significant following individual enantiomer
doses. This result was not unexpected because enantiomers
could be compared by a paired t test following racemate
administration and an unpaired t test was necessary to
compare the two separate groups of dogs receiving individual
enantiomers. The power of a paired t test for enantiomer
comparisons following pirmenol racemate made the detection
of statistically significant differences more likely relative to
enantiomer comparisons following individual enantiomer
doses.
Plasma protein binding was more extensive for (-)-pirmenol
than for (+)-pirmenol. Mean fraction unbound was 58%
higher (S) for (+)-pirmenol than for (-)-pirmenol following the
racemate dose, and 7% higher (NS) for (+)-pirmenol following
individual enantiomer doses. Plasma protein binding was
linear for most dogs, with only three of the 13 dogs tested
showing nonlinear protein binding. Of these three dogs, one
received pirmenol racemate and the other two received (+)-
pirmenol alone.
Higher (-)-pirmenol concentrations observed for total pir-
menol can, at least in part, be explained by differences in
extent of plasma protein binding. Differences in total pirme-
nol enantiomer concentrations were minimized when unbound
concentrations were compared. Clearance of unbound (-)-
pirmenol was only 16% lower (S) following administration of
the racemate and 21% lower (NS) following administration
of the individual enantiomers, relative to unbound (+)-
pirmenol. Distribution volume terms for unbound drug were
similar for both (+)- and (-)-pirmenol, whether administered
as pirmenol racemate or as the individual enantiomers. As a
result of lower clearance for unbound (-)-pirmenol with no
enantiomer difference in unbound pirmenol distribution vol-
ume, half-life was longer for unbound (-)-pirmenol than for
unbound (+)-pirmenol.
Possible interaction between enantiomers was assessed by
comparing pharmacokinetic parameters for each enantiomer
given as the racemate or as the individual enantiomer by an
unpaired t test. Several distribution volume terms (i.e.,
unbound (+)-pirmenol V1, total (-)-pirmenol V1, and unbound
(-)-pirmenol V1, Vss, and Varea) were 30-60% greater (S)
following individual enantiomer administration compared
with racemate. Lower distribution volume following the
racemate compared with the individual enantiomers may
suggest the possibility of decreased tissue binding when both
enantiomers are present compared with when each enanti-
omer is administered alone. In contrast, there were no
significant differences between enantiomer alone and enan-
tiomer in the presence of its optical antipode with respect to
clearance, half-life, and plasma protein binding.
Pharmacodynamics of Pirmenol Racemate and
EnantiomerssBaseline arrhythmia ranged from 138 to 172
PVCs/min, 118 to 199 PVCs/min, and 149 to 207 PVCs/min
in dogs receiving (+)-pirmenol, (-)-pirmenol, and pirmenol
racemate, respectively. Expressed as percent of total beats,
baseline values ranged from 89-97% PVCs, 92-100% PVCs,
and 80-100% PVCs in dogs receiving (+)-pirmenol, (-)-
pirmenol, and pirmenol racemate, respectively. Therefore,
similar degrees of arrhythmia were used for comparison
Table 1−Mean (±SD) Pharmacokinetic Parameters of Pirmenol Enantiomers in Coronary Artery Ligated Dogs Following a Single Intravenous Dose of 5
mg/kg Given as Pirmenol Racemate ( n ) 5), (+)-Pirmenol ( n ) 4), or (−)-Pirmenol ( n ) 4)a
Racemic Dose Enantiomeric Dose
Parameterb (+)-Pirmenol (−)-Pirmenol Significance p Value (+)-Pirmenol (−)-Pirmenol Significance p Value
Total Pirmenol
t1/2 1.93 (0.62) 2.46 (1.13) NS 0.094 2.30 (1.66) 2.40 (0.86) NS 0.916
AUC(0−∞) 1.77 (0.28) 3.44 (0.82) S, (−) > (+) 0.0025 3.31 (0.97) 4.76 (1.05) NS 0.088
MRT 2.46 (0.52) 3.20 (1.08) NS 0.062 2.74 (1.76) 3.11 (0.89) NS 0.723
CL 24.0 (4.0) 12.7 (3.3) S, (+) > (−) 0.0001 26.9 (7.9) 18.3 (5.0) NS 0.118
V1 1.95 (0.62) 1.36 (0.43) S, (+) > (−) 0.0036 2.47 (0.62) 2.24 (0.30) NS 0.528
Vss 3.49 (0.62) 2.35 (0.68) S, (+) > (−) 0.0010 4.40 (2.79) 3.28 (0.57) NS 0.460
Varea 3.92 (1.10) 2.60 (1.04) S, (+) > (−) 0.0006 5.42 (3.89) 3.64 (0.87) NS 0.406
Unbound Pirmenol
t1/2 1.33 (0.37) 1.57 (0.50) S, (−) > (+) 0.020 1.52 (0.48) 2.00 (0.70) NS 0.305
AUC(0−∞) 0.601 (0.078) 0.727 (0.139) S, (−) > (+) 0.028 1.03 (0.19) 1.34 (0.36) NS 0.166
MRT 1.85 (0.49) 2.21 (0.68) S, (−) > (+) 0.017 1.93 (0.47) 2.71 (0.93) NS 0.185
CL 70.3 (9.8) 59.4 (13.7) S, (+) > (−) 0.021 83.2 (13.8) 65.4 (17.3) NS 0.159
V1 4.84 (0.72) 5.09 (0.95) NS 0.364 6.87 (1.69) 7.66 (1.38) NS 0.495
Vss 7.64 (1.74) 7.57 (1.75) NS 0.864 9.73 (3.33) 10.0 (1.0) NS 0.902
Varea 7.97 (2.02) 7.78 (1.87) NS 0.649 11.2 (4.8) 10.5 (0.9) NS 0.797
fu 0.343 (0.040) 0.217 (0.051) S, (+) > (−) 0.0001 0.319 (0.055) 0.297 (0.108) NS 0.725
a Body weight ) 10.0 ± 1.2 kg for racemate dose group (mean ± SD); 9.7 ± 1.5 kg for (+)-pirmenol dose group (mean ± SD); and 11.6 ± 1.1 kg for (−)-pirmenol
dose group (mean ± SD). b Parameter definitions: t1/2 ) terminal-phase half-life (h); AUC(0-∞) ) area under the plasma concentration−time curve extrapolated to
infinity (µg‚h/mL); MRT ) mean residence time (h); CL ) plasma clearance (mL/min/kg); V1 ) volume of the central compartment (L/kg); Vss ) volume of distribution
steady-state (L/kg); Varea ) volume relating plasma drug concentration to amount in the body during the log-linear terminal phase (L/kg); fu ) fraction unbound in
plasma.
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between treatment groups (Table 2). In previous studies of
pirmenol racemate, Mertz and co-workers1,2 showed that the
arrhythmia produced with the Harris dog model was stable
for a treatment period of at least 6 h on the day after surgery.
Arrhythmia was monitored for 4 h post-dose in this study, so
the observed reduction in PVCs can be attributed to a drug
Figure 1sMean (±SE) plasma concentrations of total (A) and unbound (B) pirmenol enantiomers following a single iv 5-mg/kg racemic pirmenol dose to coronary
artery ligated dogs (n ) 5); mean (±SE) plasma concentrations of total (C) and unbound (D) pirmenol enantiomers following a single iv 5-mg/kg (+)-pirmenol dose (n
) 4) and (−)-pirmenol dose (n ) 4) to coronary artery ligated dogs.
Table 2−Statistical Comparison of Mean ( ±SD) Pharmacodynamic Parameters of Pirmenol Enantiomers and Pirmenol Racemate in Coronary Artery
Ligated Dogs Following a Single Intravenous Dose of 5 mg/kg Given As Pirmenol Racemate ( n ) 5), (+)-Pirmenol ( n ) 4), or (−)-Pirmenol ( n ) 4)
Dose
Parametera Racemate (+)-Pirmenol (−)-Pirmenol Significance p Value
Baseline Arrhythmia
% of Total Beats 94 (8) 94 (3) 96 (4) NS 0.804
PVCs/min 172 (24) 149 (15) 158 (45) NS 0.550
Total Pirmenol
EC50 1.43 (0.65) 1.20 (0.28) 1.08 (0.33) NS 0.532
S 2.77 (2.75) 2.27 (0.74) 4.76 (2.82) NS 0.325
EC90 5.72 (3.75) 3.51 (0.82) 1.96 (0.77) NS 0.116
r2 0.566 (0.148) 0.745 (0.108) 0.769 (0.181)
Unbound Pirmenol
EC50 0.41 (0.16) 0.43 (0.10) 0.35 (0.18) NS 0.743
S 2.17 (1.78) 2.18 (0.67) 4.70 (2.59) NS 0.124
EC90 1.82 (1.20) 1.33 (0.47) 0.62 (0.34) NS 0.145
r2 0.550 (0.152) 0.748 (0.107) 0.767 (0.180)
a EC50 ) plasma drug concentration at 50% of Emax (µg/mL); EC90 ) plasma drug concentration at 90% of Emax (µg/mL).
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effect without significant contribution from a natural return
of sinus rhythm with time following surgery.
Both pirmenol enantiomers were equally effective in ar-
rhythmia suppression. Pirmenol racemate also showed PVC
reduction similar to that of the individual enantiomers at
equivalent doses. For all three treatments, suppression of the
arrhythmia was complete or nearly complete by the end of
the 5-min infusion. Following the infusion, PVCs returned
with time as drug was being cleared from the systemic
circulation (Figure 2).
Pharmacodynamic parameters are listed in Table 2 for total
and unbound pirmenol enantiomers and racemate. Percent
reduction in PVCs was correlated with drug concentration
with a sigmoid Emax model (eq 8). Coefficient of determination
(r2) values ranged from 0.405 to 0.901, and were similar for
all drug species. Low r2 values were probably a result of
spontaneous variability in the effect parameter (PVCs/min),
which has been described by Harris.16 Mean EC50 values were
similar for (+)-pirmenol, (-)-pirmenol, and pirmenol racemate,
ranging from 1.08 to 1.43 µg/mL for total drug (NS) and from
0.35 to 0.43 µg/mL for unbound drug (NS). Values for the
slope factor were approximately twofold greater (NS) for (-)-
pirmenol than for (+)-pirmenol or pirmenol racemate. Simi-
larly, therapeutic plasma concentrations reflected by the EC90
values were nearly two- to threefold lower (NS) for (-)-
pirmenol as compared with (+)-pirmenol and pirmenol race-
mate; however, these differences were not statistically sig-
nificant (Table 2). Effect-concentration curves simulated
with mean EC50 and S values reflect the totality of individual
data reasonably well for both total and unbound pirmenol
racemate (Figure 3). Similar effect-concentration curves
were also observed following (+)-pirmenol and (-)-pirmenol.
To better highlight these treatment comparisons, the general
profiles of effect-concentration curves based on mean param-
Figure 2sMean (±SE) effect versus time profiles in coronary artery ligated dogs
following a single iv dose of 5 mg/kg of (+)-pirmenol, (−)-pirmenol, or pirmenol
racemate.
Figure 3sEffect−concentration profiles of total and unbound pirmenol racemate
in coronary artery ligated dogs following a single iv dose of 5 mg/kg of pirmenol
racemate. The solid line represents the hypothetical effect−concentration curve
based on mean EC50 and S values as displayed in Table 2. Individual data are
superimposed on this curve.
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eter estimates for (+)-pirmenol, (-)-pirmenol, and pirmenol
racemate are displayed in Figure 4.
Although the mean EC90 appeared to be lower for (-)-
pirmenol (NS), greater sensitivity of sodium channels to (-)-
pirmenol is not likely because Nakaya et al.22 showed no
stereoselective interaction of pirmenol enantiomers with the
sodium channel in guinea pig papillary muscle. Similarity
of the phenyl and pyridine rings at the chiral center of the
chemical structure of pirmenol was suggested by Nakaya et
al.22 to be responsible for the lack of stereoselectivity in sodium
channel blocking activity. Parameter differences between
pirmenol enantiomers may have resulted from different dogs
being used in each treatment group and the relatively small
number of animals studied. A larger sample size may be
necessary to determine if either pirmenol enantiomer was
actually more potent. However, it is unlikely that the data
for (+)-pirmenol and (-)-pirmenol reflect an actual difference
in EC90 between enantiomers. If this were true, then one
would predict the EC90 of racemate to be intermediate between
the (+)-pirmenol and (-)-pirmenol values. In fact, EC90 values
for racemate were apparently larger (NS) than for individual
enantiomers, which probably reflects the different animals
studied. In addition, individual effect-concentration data for
the (+)-pirmenol and (-)-pirmenol doses show a large degree
of overlap, with each enantiomer dose extending over a wide
range of effect and concentration values (Figure 5).
The severity of arrhythmia may also be a factor in deter-
mining the therapeutic concentration required for PVC sup-
pression because Steffe et al.2 showed that higher doses were
required for treatment of more severe arrhythmia occurring
on the first day as compared with the second day after
coronary artery ligation. In another study, minimum effective
therapeutic concentration for 100% PVC suppression by total
pirmenol racemate was estimated as 1.0 µg/mL for low-rate
arrhythmias (average baseline, 53% PVCs) and 2.3 µg/mL for
high-rate arrhythmias (average baseline, 96% PVCs) during
continuous iv infusion in coronary artery ligated dogs.1 In
this context, high EC90 values were generally associated with
the most severe arrhythmias, and the highest mean baseline
PVC rate (PVCs/min) was in the group receiving pirmenol
racemate (NS). Although not statistically different, mean
EC90 values for the racemate were higher than for the (+)-
pirmenol and (-)-pirmenol groups with lower mean baseline
PVC rates (Table 2).
Mean ((SD) minimum effective plasma concentration,
defined as the concentration at the last minute of statistically
significant decrease in %PVCs from the predose value, was
reported as 1.1 ( 0.3 µg/mL (corresponding to 65% reduction
in PVCs) in coronary artery ligated dogs; complete arrhythmia
suppression was observed at concentrations ranging from 0.7
to 4 µg/mL.3 These literature values, as well as those reported
by Mertz and Steffe,1 correspond favorably with the mean
effective therapeutic concentration (EC90) of 5.72 µg/mL (range
Figure 4sComparison of fitted effect−concentration curves using mean EC50 and
S estimates from Table 2 for total and unbound drug following a single iv dose
of 5 mg/kg of (+)-pirmenol, (−)-pirmenol, or pirmenol racemate to coronary artery
ligated dogs. Figure 5sComparison of pooled effect−concentration data for total and unbound
drug following a single iv dose of 5 mg/kg of (+)-pirmenol or (−)-pirmenol to
coronary artery ligated dogs.
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1.19 to 8.83 µg/mL) for total racemic pirmenol obtained from
fitting effect-concentration data to a sigmoid Emax model in
this study.
ConclusionssPlasma total (-)-pirmenol concentrations
exceeded those of (+)-pirmenol, with statistically different
values for AUC(0-∞) [94% higher for (-)-pirmenol], CL [47%
lower for (-)-pirmenol], and Vss [33% lower for (-)-pirmenol]
following the pirmenol racemate dose. Similar trends were
observed for pirmenol enantiomers administered individually;
however, the differences did not achieve statistical signifi-
cance. (+)-Pirmenol showed a 58% higher unbound fraction
in plasma than (-)-pirmenol following racemate administra-
tion, so differences between pirmenol enantiomer pharmaco-
kinetic parameters based on unbound plasma drug concen-
trations were dramatically reduced. Unbound pirmenol
distribution volumes were nearly identical for both enanti-
omers, and small statistical differences were observed for
unbound AUC(0-∞) [17% higher for (-)-pirmenol] and un-
bound clearance [16% lower for (-)-pirmenol] following the
racemate. Therefore, differences between total pirmenol
enantiomer pharmacokinetics can be mostly explained by
stereoselective plasma protein binding.
The antiarrhythmic response of coronary artery ligated dogs
to pirmenol was similar for both enantiomers and for race-
mate. Reduction in PVCs as a function of plasma pirmenol
concentration was adequately described by a sigmoid Emax
model. The EC50 values were similar for (+)-pirmenol, (-)-
pirmenol, and pirmenol racemate, but minimum effective
plasma concentration (90% PVC suppression) was nearly two-
to threefold lower for (-)-pirmenol than for (+)-pirmenol or
pirmenol racemate. The EC90 differences may be a conse-
quence of different animals being used in each treatment
group and the limited number of animals studied. Overall,
no statistically significant differences were observed in EC50,
S, and EC90 between dogs treated with (+)-pirmenol, (-)-
pirmenol, or pirmenol racemate.
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